TrialSignal
Clinical trial intelligence report
The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04403698
Status
COMPLETED
Phase
PHASE2
Sponsor
University Hospital, Ghent
Executive brief
Investment-Ready Snapshot
It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04403698
Indication
Erosive Osteoarthritis
Modality
monoclonal antibody
Target
Alendronate Effervescent Oral Tablet
Intervention
Alendronate Effervescent Oral Tablet
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.